Medivation, Astellas Begin Enzalutamide Phase 2 Study In Advanced Breast Cancer

(RTTNews) - Biotechnology company Medivation Inc. (MDVN), and Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc., Wednesday said it initiated the Phase 2 clinical trial studying the safety and efficacy of enzalutamide in combination with exemestane in women with advanced breast cancer that is estrogen receptor positive or progesterone receptor positive and human epidermal growth factor receptor 2 normal.

Medivation and Astellas' clinical development plan for enzalutamide in breast cancer also includes an ongoing Phase 2 trial evaluating enzalutamide as a single agent for the treatment of advanced androgen receptor positive, triple-negative breast cancer. The global study initiated enrollment in June 2013.

"Exemestane is a commonly used aromatase inhibitor in patients whose tumors express either the estrogen or progesterone receptor. It is our hope that inhibiting androgen receptor signaling with enzalutamide in combination with exemestane will provide benefit beyond the inhibition of estrogen and progesterone signaling in patients with advanced breast cancer." the company said.